Adrenomed is a German biopharmaceutical company specialized in restoring vascular integrity in life-threatening conditions. The developed pioneering biomarker-guided approach is shifting sepsis treatment towards precision medicine, ensuring that patients get the right drug for their underlying disease mechanism.
Lead product candidate is Adrecizumab. A clinical stage, first-in-class monoclonal antibody that targets the vasoprotective peptide Adrenomedullin, to treat conditions associated with increased vascular leakage, endothelial barrier dysfunction and shock. Lead indication is septic shock.
Improved organ function, reduction of mortality and validation of mode of action has been demonstrated in biomarker guided proof-of-concept Phase II clinical trial (AdrenOSS-2) in 301 septic shock patients.
Excellent safety and tolerability was demonstrated confirming data from regulatory preclinical as well as clinical phase I trials. Building on the results from the AdrenOSS-2 trial, Adrenomed is now planning a pivotal clinical trial program.
TAM is 50-60% of the septic shock market. Business is effectively secured by a strong IP position. https://adrenomed.com/
CEL-SCI Corporation [NYSEAMERICAN: CVM]
CEL-SCI Corporation a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer, infectious and autoimmune diseases. CEL-SCI recently completed a pivotal global Phase 3 study in head and neck cancer and reported top line data showing a significant survival benefit with no safety issues in patients who received its Multikine® immunotherapy prior to a standard of care treatment of surgery plus radiotherapy. 928 patients were randomized into two treatment arms determined by risk of recurrence post-surgery following National Cancer Comprehensive Network (NCCN) guidelines. 41.2% of patients were prescribed surgery + radiation (no chemotherapy); 50.6% were prescribed surgery + chemoradiotherapy; and 8.2% of patients who did not receive radiation or chemotherapy due to doctor, family, and patient decisions were excluded from the analysis. In the treatment arm that was prescribed surgery + radiation (no chemotherapy), Multikine immunotherapy produced a statistically significant 14.1% 5-year survival benefit. 62.7% of patients treated with Multikine were alive 5-years after treatment as compared to 48.6% for patients who did not receive Multikine.
Patients who received chemotherapy (cisplatin) as part of their prescribed standard of care treatment did not benefit from Multikine, indicating that cisplatin may have negated Multikine’s survival benefits. No safety issues were found in the whole study population.
CEL-SCI is preparing to file for FDA approval for this population comprising about 210,000 patients per year worldwide. Multikine has received Orphan Drug designation from the FDA for advanced primary squamous cell carcinoma of the head and neck, an unmet medical need for which the FDA has not approved a new treatment in decades. CEL-SCI is also developing a novel vaccine for the treatment of rheumatoid arthritis using the LEAPS technology platform which has been supported by multiple grants from the NIH.
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer. Cytovia’s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site. Both platforms offer optionality to clinicians and can also be used synergistically. Cytovia’s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).
GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) and, more recently, neuropsychiatric syndromes in Post-COVID.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies. https://www.markertherapeutics.com/
STALICLA is a Swiss clinical stage biotech company deploying and applying a first in class discovery platform to bring precision medicine to patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).
STALICLA has assembled a world-class team of 26 seasoned drug developers, clinicians, data scientists and computational biologists.
DEPI, the company's NDD precision medicine platform leveraging on ML and transcriptomics technology, has reached proof of concept for its capacity to characterize biologically similar subgroups of patients within highly variable populations of patients with neurodevelopmental disorders, and to further identify tailored treatment candidates.
To further advance its drug discovery platform and pipeline, STALICLA has established strong networks within top tier research and clinical centers in the United States and Europe.
STALICLA currently has one precision medicine candidate in the clinic and plans to bring two assets into Phase 2 in 2022.
The company is also advancing collaborative alliances with strategic third party pipelines.
STALICLA has raised UDS 27M to date and is rapidly scaling its platform and clinical development activity. For more information, please visit company's website.
TauRx was founded in 2002 in Singapore, with research facilities in Aberdeen. Its mission is to discover, develop and commercialise new products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation. Our scientific roots lie in the research of co-founder Professor Wischik, whose early work led to the first identification of tau protein as the structural constituent of the neurofibrillary tangles originally discovered by Alzheimer. Tau pathology is widely recognised as a principal driver of clinical dementia in Alzheimer’s disease and TauRx’s experimental tau aggregation inhibitors (TAIs) target the formation or aggregation of tau protein ‘tangles’ in the brain. Three completed phase 3 studies of a second-generation TAI have informed the design of the fully randomised and pivotal LUCIDITY study, with results expected mid-2022.
Genting TauRx Diagnostic Centre Sdn Bhd, a company established in Malaysia, and its wholly owned Aberdeen-based subsidiary GT Diagnostics (UK) Limited (collectively, “GT Diagnostics”) was founded as a collaboration between Genting Berhad, a Malaysian company, and TauRx Pharmaceuticals Ltd Group, with the vision to change the diagnostic landscape and market in dementia. Its mission is to develop and provide much needed tools required for the early diagnosis and monitoring of disease progression in dementia; from tools that can be used in the comfort of one’s home to tools that require administration by experts.
Early diagnosis of Alzheimer’s disease, Mild Cognitive Impairment and other dementias is highly relevant not only for new therapeutics to be most effective but also to empower patients with knowledge. GT Diagnostics develops readily deployable e-platform tools for home use as well-being apps, alongside professional tools for expert use targeting the diagnosis and monitoring of dementias. Our tools are designed to be made available through various channels and service providers, ranging from financial and professional service providers, clinicians, residential and non-residential care centres, to specialised dementia centres.
The market is in desperate need of an effective and safe treatment for AD, with patient access being supported by better and more efficient diagnostics. If the Lucidity trial results support regulatory approvals, there will be the prospect of a novel oral treatment for Alzheimer's disease developed with affordability and accessibility in mind, and which has a reassuring safety profile supported by a large bank of trial data.
Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with a single molecular construct.
Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional mRNA in different disease contexts – making RNA druggable in new therapeutic areas. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards a first in-human/proof-of-concept clinical study in SUI while advancing its platform.
Based in Basel, Switzerland and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient.
AbilityPharma is a clinical-stage biopharmaceutical company committed to develop its first-in-class drug, ABTL0812, an oral targeted anticancer compound causing cell death by autophagy.
ABTL0812 causes irreversible cytotoxic autophagy selectively in cancer cells through the induction of ER Stress and AKT blockade. Besides being efficacious as single agent, ABTL0812 has synergistic effect with chemotherapy and has synergistic effect with IO therapies (anti-PD1) and acts on the tumor microenvironment turning cold tumors into hot (immunogenic) tumors.
In 2020 we finished the phase 2a first-line clinical trial in endometrial and lung cancer patients with very positive results, which show that ABTL0812 combined with chemotherapy is much superior to chemotherapy alone.
In 2021, we have started a phase 2b, double-blind, placebo-controlled trial in 150 patients with metastatic pancreatic cancer as first-line therapy in combination with FOLFIRINOX in Spain, USA, France and Israel.
To fund this trial, we have secured 13 M€ in 2020, both in capital and grants, including a grant from the EIC Accelerator Program of the European Commission H2020 (2.4 M€ grant, 2.8 M€ Equity investment) and a 1.9 M USD NIH R01 grant in the FDA Orphan Disease Program. Additional funds are being raised. www.abilitypharma.com/
Abliva AB [STO: ABLI]
Abliva is focused on becoming the leading biopharmaceutical company in mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet medical need. The company will build a fully integrated research, development, and commercial organization, developing innovative therapeutics and taking them directly to the patients.
We are advancing mRNA Lightning, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale automated phenotypic screening in live biology with AI mRNA image analysis. We develop our own pipeline and partner with pharma on additional targets. https://www.animabiotech.com/
Arctic Bioscience is a biotech company developing pharmaceutical and nutraceutical products based on the unique properties of herring roe oil, composed of complex bioactive marine compounds, including lipids essential to maintaining cell membranes. The nutraceutical products contain lipids which contribute to the normal functioning of brain, heart and vision.
The company is developing a novel drug candidate (HRO350) for mild-to-moderate psoriasis, a large global patient population where there is substantial need for effective, convenient and cost-effective new medicines with beneficial safety profiles. Nutraceuticals from Arctic Bioscience are sold worldwide as bulk ingredients to other companies making dietary supplements (B2B) and as finished goods under the ROMEGA™ brand (B2C), with significant expansion potential all channels and regions.
To support its long-term growth strategy, Arctic Bioscience is planning a state-of-the-art manufacturing facility in Ørsta. Easy access to the raw material and proprietary production processes will increase control of the value chain, improve margins and enable large-scale, high-quality manufacturing.
Arctic Bioscience is led by a highly competent team with significant expertise developing marine oils and extensive experience from some of the world’s leading pharmaceutical, technology and financial services companies.
Arctoris is a platform company founded and headquartered in Oxford, UK with additional hubs in Boston (US) and Singapore. Arctoris conducts integrated drug discovery projects from idea to IND, combining its experienced team of biotech and pharma veterans with its proprietary technologies.
Thanks to end-to-end automation of research processes from experiment design and execution to full data/ metadata capture and analysis, Arctoris enables better decisions based on better data, leading to higher success rates and a faster progression of programs towards the clinic.
Arctoris pursues its internal pipeline of small molecule inhibitors in different indications, and also engages in both fee-for-service and risk-share agreements in small molecule and biologics discovery. Arctoris is a trusted partner for biotech and pharma companies in the US, UK, Germany, Australia, Korea, Hong Kong, and many other countries.
Atamyo Therapeutics' mission is to bring a new generation of best-in-class gene therapies to patients suffering from neuromuscular diseases, with an initial focus on Limb-Girdle Muscular Distrophies (LGMDs).
Atamyo is a spinoff of Genethon, a worldwide leader in gene therapy R&D applied to neuromuscular diseases. As such, Atamyo leverages Genethon’s 30 years proven track record in gene therapy development, and benefits from a full spectrum of expertise and technologies that few gene therapy companies possess.
Atamyo has a robust pipeline of 5 programs with in vivo POC established, including an IND-ready program targeting LGMD-R9 (FKRP) and 2 additional programs with CTA filing planned within 12 months, targeting respectively LGMD-R5 and LGMD-R1.
This pipeline incorporates breakthrough technologies allowing enhanced efficacy and safety gene therapies, including a novel capsid with enhanced muscle-tropism and liver detargeting. Atamyo also benefits from industry-leading manufacturing process that ensure high quality and yield.
LGMDs are associated with progressive atrophy and weakness of the muscles, with onset in childhood and teens, leading to a loss of ambulation in almost all patients. In addition, LGMD patients suffer from contractures, scoliosis, pain, and most severe patients have respiratory insufficiency and/or cardiac impairment leading to a potential mortality.
Atamyo's seasoned management has a large experience in developing biotech programs and gene therapies.
Avectas is a cell engineering company that has pioneered - SOLUPORE® - a proprietary simple, highly effective automated transfection system to enable efficient and safe genetic modification, accelerating the manufacture of cells for the next generation of immuno-oncology therapies.
Avectas is a private, international company with research facilities in Dublin, Ireland and Toronto, Canada as well as an office in Cambridge MA, USA. It has over 30 employees and is led by a team of highly experienced pharmaceutical executives, who are supported by a world class Scientific Advisory Board of cancer cell therapy experts. The Company has raised over US$40m to date.
BIOASIS TECHNOLOGIES, INC. [TSXV:BTIV / OTCQB:BIOAF]
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease modifying treatments for brain-related diseases and disorders.
BioInvent International AB [Nasdaq Stockholm: BINV]
BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit.
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a diversified portfolio of cell therapies at different stages ranging from pre-clinical programs in immunomodulation to mid stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation. Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium.
Chimeric Therapeutics is a clinical stage cell therapy company focused in oncology.
We believe that novel cell therapies have the promise to cure cancer.
Our mission is to bring that promise to life for more patients by discovering, developing and commercializing cell therapies with the most curative potential.
Our lead asset, CHM 1101 (CLTX CAR T), is a novel CAR T cell therapy that is currently being developed for patients with solid tumours. The initial phase 1 clinical trial with CHM 1101 is currently underway for patients with recurrent and progressive glioblastoma. Plans are in progress to initiate a second clinical trial for patients with other solid tumours including metastatic melanoma and potentially prostate and colorectal cancer.
Chimeric recently announced the expansion of our pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.
Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.
Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout. Dyve’s transdermal delivery science platform overturns the traditional limitations of administering therapies. It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs.
EIP Pharma is a Boston-based CNS therapeutics-directed clinical stage pharmaceutical company that is led by a top-tier management team that has a track record in developing major, innovative medicines. The company is developing neflamapimod, an oral specific kinase inhibitor that in preclinical studies demonstrated positive effects on both functional and neurodegenerative outcomes. In the clinic, neflamapimod has been evaluated in more than 300 patients and volunteers, with completed phase 2 clinical studies in Alzheimer’s disease and dementia with Lewy bodies (DLB) which demonstrated target engagement and proof-of-principle, respectively. Results of the AscenD-LB Phase 2 clinical study with neflamapimod that demonstrated proof-of-principle for neflamapimod as a treatment for dementia with Lewy bodies (DLB) were presented at a major medical conference (Clinical Trials in Alzheimer's Disease, CTAD) in November 2020. In that study, neflamapimod significantly improved cognition, as assessed by a DLB-specific Neuropsychological Test Battery (NTB) designed to evaluate attention and executive function. In addition, neflamapimod demonstrated a statistically significant and clinically relevant magnitude effects on the CDR Sum of Boxes and the Timed Up and Go Test, a well validated clinical endpoint that assesses functional mobility. Further clinical data from the AscenD-LB study are to be presented at oral communications at CTAD in November 2021. https://www.eippharma.com/
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
The company’s lead product candidate, MOv18 IgE, is in a phase I clinical trial in folate receptor alpha positive cancer patients. This is the world’s first IgE drug to enter clinical trials. Epsilogen has constructed a novel and proprietary pipeline of anti-cancer IgE antibodies.
Herantis is a CNS focused biotech company with a compelling portfolio of disease modifying assets Cerebral Dopamine Neurotrophic Factor CDNF and xCDNF. Both assets powerfully impact a core system in the body called Proteostasis, a key biological system which goes wrong in many neurodegenerative diseases. Both assets have demonstrated promising potential to significantly improve neuronal survival and thus slow or stop the progression of Parkinson’s and other neurodegenerative diseases.
Immunicum, based in Sweden and the Netherlands, is leveraging its unparalleled expertise in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. The company addresses difficult-to-treat established tumors and tumor recurrence, representing the biggest challenges for today’s cancer therapy.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world-leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome analytics. These capabilities enable the transition to precision medicine in the microbiome, whereby microbial signatures linked to phenotype enable both product design and patent stratification, thus accelerating and de-risking the development process.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. After NOXXON’s lead program NOX-A12 delivered final top-line data with encouraging overall survival and safety profile from a combination trial with an anti-PD-1 immuno-oncology checkpoint inhibitor in metastatic colorectal and pancreatic cancer patients in September 2020, the company announced in July 2021 its Phase 2 study to further evaluate safety and efficacy of NOX-A12 in combination with anti-PD-1 and two different chemotherapy regimens as second-line therapy in patients with pancreatic cancer.
The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. A trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered interim data from the low- and mid-dose cohorts showing consistent tumor reductions. The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021. NOXXON plans to develop NOX-E36 in patients with solid tumors.
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other genetically validated neurodegenerative diseases with next-generation precision medicines. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients.
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
Sprint Bioscience develops small-molecule oncology first-in-class preclinical drug projects. These out-licensed to global drug companies at the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 747 million in milestone payments, and in addition royalties on sales.
AC BioScience is a Swiss biotech company pioneering the development of groundbreaking therapies in angiogenic cancer treatment and immuno-oncology. Two of its lead molecules will enter clinical trials in 2022.
The company’s co-founders and the core team combine scientific excellence with seasoned management with a strong track record in execution and in turning scientific inventions into products with large revenue potential. Our business model is to develop proprietary drugs up to PoC stage.
One of its two lead molecules ACB2003.4 will commence clinical trials Phase II/III in Q1 2022 for the treatment of metastatic pancreatic adenocarcinoma based on solid preclinical and FDA-approved Phase I data. If PoC can be achieved with this groundbreaking angiogenic combination cancer treatment for pancreatic cancer, this would open the way for the treatment of most other solid hypoxic cancers.
The company's immuno-oncology molecule ACB1801 has shown exceptional preclinical results in combination therapies in enhancing the efficacy of checkpoint-inhibitor immune therapy, and the molecule will enter clinical stage in late 2022. ACB1801 modulates the malignant phenotype in order to improve MHC-1 mediated antigens presentation, and thereby potentiates the efficacy of anti PD-1 therapy.
The company is currently initiating a Series A Round to finance clinical trials and to up-scale the development of its product pipeline. Towards this end, we seek financial investors and/or strategic Pharma partners.
Adaptate is a pre-clinical stage immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to engage with and modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.
Our antibodies target gamma delta T cells, a unique class of lymphocytes capable of combining the speed of innate immunity with the selectivity of adaptive immune response.
Our antibodies selectively target only gamma delta T cells thereby offering the opportunity for superior efficacy and safety over and above conventional immunomodulatory therapies such as pan T cell activators.
Gamma delta T cells recognise malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than any one specific antigen.
Gamma delta T cells are located throughout the blood and tissues of the body where they perform a crucial immunosurveillance role, recognising and eradicating stressed and malignant ‘self’. Unlike conventional T-cells, tissue-resident gamma delta T cells are primed for the hypoxic, low nutrient solid tumour environment and form a large proportion of tumour infiltrating lymphocytes (TILs) in a wide variety of cancers.
AlgoTx is a European biotech developing novel drugs for complex pain.
AlgoTx' lead program ATX01 is a non-opioid topical treatment for the pain of Chemotherapy-Induced Peripheral Neuropathy. ATX01 is currently in Phase I and will enter Phase II development in CIPN in early 2022.
ATX01 also obtained Orphan Disease Designation from FDA for a rare and debilitating form of peripheral neuropathy.
Apaxen develops novel drug treatments for patients with Pulmonary Arterial Hypertension and other chronic inflammatory diseases. Its lead compound MFC-1040 binds to MIF, inhibiting multiple inflammatory processes. MFC-1040 is expected to start clinical development in 2022.
Aprinoia Therapeutics Inc. is a clinical stage biotech company developing novel therapeutics and precision diagnostics for the treatments of neurodegenerative diseases with unmet medical needs.
The Company has developed unique small molecules, antibodies, and degraders platforms, targeting pathological aggregated proteins (e.g. Tau, alpha-Synuclein, TDP43) that contribute to the pathogenesis of rare dementia or movement disorders, including PSP (progressive supranuclear palsy), MSA (multiple system atrophy), and FLD (frontotemporal dementia), as well as common diseases such as Alzheimer’s (AD) and Parkinson’s diseases (PD).
One of the unique features of Aprinoia’s therapeutic modalities is their ability to target only the toxic protein aggregates, while sparing the normal monomeric proteins. This unique feature enables the development of targeted therapeutics and accurate diagnostic tools.
Aprinoia is developing Tau-PET tracer (18F-APN-1607), currently in phase 3 clinical development in China and phase 2 in the US, for precise diagnosis of various neurodegenerative diseases. 18F-APN-1607 has been validated in 1600+ human subjects, demonstrating wide utilities for AD and non-AD tauopathies, including PSP, FTD, and CBD (corticobasal degeneration) to differentially quantify the amount and spatial distribution of tau protein abnormality in those patients.
In addition to preparing Tau-PET commercialization in 2023, the Company is leveraging its Tau-PET tracers to enable clinical research for therapeutic development, including innovative trial designs and establishing global trial-ready cohorts.
The Company currently has 4 therapeutic programs in preclinical development, including Tau modulators and Tau antibodies for tauopathies (e.g. PSP/FTD/AD), as well as two protein degraders (targeting Tau or a-Syn) for tauopathies and synucleinopathies (e.g. PD, MSA, Lewy body dementia).
C4U Corporation is a biotechnology venture company founded in March 2018, by Dr. Tomoji Mashimo (currently Professor of University of Tokyo) et al. We have developed proprietary gene editing techniques such as one using CRISPR-Cas3 that is characterized by its unprecedentedly high target sequence specificity (no off-target, namely, safety in medical use) and large scale deletion (efficient knock-out). We are looking for alliance partners to develop innovative products and for licensees who would utilize our CRISPR-Cas3 technology. www.crispr4u.jp/en/
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development. insphero.com
Lanthio Health B.V.
Lanthio Health B.V. is a Dutch biopharmaceutical company committed to discovering and developing therapeutic peptides for severe diseases with high unmet medical need. The company is generating lanthionine-constrained peptides with high target-selectivity and stability. Lanthio Health is building a growing pipeline of receptor-specific, stabilized agonistic lanthipeptides in oncology and critical-care medicine.
Founded in 2016, Maxwell Biosciences is a preclinical stage biotech company based out of Austin, Texas – with key scientists based at Stanford and NYU - that is developing a breakthrough infectious disease & oncology drug platform. Benefitting from over $30M in non-dilutive funding and over 250 published peer-reviewed studies by institutions and governments around the world, the company’s CLAROMER™ biotechnology platform - which creates patented, virucidal, small molecule compounds called peptoids – is a potential game-changer for global health.
Minoryx is developing leriglitazone, a brain penetrant PPAR gamma agonist with the potential to become the first to market treatment for AMN, the most prevalent form of X-ALD. The company is under conversations with regulatory authorities about an approval path based on data from its completed registration phase 2/3 study. Additionally, leriglitazone also showed strong potential for the treatment of Friedreich's Ataxia (phase 2 completed) and other orphan CNS disorders.
NovaGo is a development stage biotech company focused on human antibody therapeutics targeting blood vessel and nerve growth & regeneration. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent vascular & nerve growth inhibitors and have the potential to become a safe and effective treatment in ophthalmology and central nervous system indications. NovaGo is planning to initiate clinical development of their lead molecule in 2022.
PDC*line Pharma is a clinical-stage spin-off of the French Blood Bank (EFS) that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma has initiated a clinical development in lung cancer with a new candidate (PDC*lung) and neoantigens (PDC*Neo). The company has raised nearly €34.5 M (19,5 M€ in equity and 15 M€ of non-dilutive money). The last round has been led by the Asian leading VC KIP (Ko-rean Investment Partners). In March 2019, PDC*line Pharma granted an exclu-sive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercializa-tion of PDC*lung cancer vaccine for lung cancer. The total deal value is €108M (123M$) plus significant tiered royalties on net sales in Asia. http://pdc-line-pharma.com/
ROXIANT is a preclinical stage biotech company based in Denmark
ROXIANT has a strong management team, board of directors & scientific board
ROXIANT develops first-in-class medicines against neurodegenerative diseases
ROXIANT's lead candidate RX-1 is a novel therapy for Huntington’s Disease:
– RX-1’s novel MoA counteracts the multifactorial disease pathology
– RX-1 has a novel IV-to-CNS delivery mechanism to cross the BBB
– RX-1’s in vivo proof-of-concept exhibit best-in-class potential
– RX-1 has late patent expiry
ROXIANT has strong patent protection with patents granted in all strategic markets
ROXIANT’s therapeutic platform has evidenced broad therapeutic potential
ROXIANT is in active dialogue for COVID-19 out-licensed partnership
ROXIANT closes its EUR 3.8 million Seed round in Q4 2021
Shaperon is a clinical-stage biotech company based in Korea. We are developing novel inflammasome inhibitors(small molecule) targeting immune-mediated inflammatory disorders. Clinical stage programs are...
Atopic dermatitis (topical, phase 2 on-going) - interim analysis shows a great EASI improvement - excellent safety profile - oral formulation in development
COVID-19 pneumonia (IV, phase 2 completed) - significant clinical remission compared with the standard of care - reduces the time required for supplemental oxygen therapy
Alzheimer's disease (oral, phase 1 IND submitted) - targeting microglia cell - neuro-inflammatory signs such as inflammasomal activities, pro-inflammatory cytokines, amyloid beta, etc., significantly reduced
Sepsis (IV, phase 1 completed) - higher survival rates in LPS, CNP septic mice model - excellent safety and tolerability profile
Other than small molecule programs, we also have nanobody-based anti-cancer, anti-viral therapeutics such as
anti-CD47 & PD-L1 bispecific (pre-clinical) - nanobody-based structure - human RBC binding minimized with high blocking potency
Tollys is a biopharmaceutical company developing innovative specific TLR3 agonists as a next generation immunotherapy against cancer.
Tollys discovered and patented a family of TLR3 agonists and selected TL-532 as its lead-candidate. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor. The specificity for the TLR3 receptor and its defined 70-base pair sequence differentiates TL-532 from all other TLR3 agonists tested to date in clinical trials.
The preclinical data generated by Tollys demonstrated the anti-tumoral and life-long auto vaccination induced by TL-532 treatment and its excellent tolerability. The unique TLR3-mediated selective induction of apoptosis in tumor cells was demonstrated both in animals and in patient tumor samples. The specific and long-lasting immune responses were also clearly shown in animal models.
Founded in 2015 by senior scientists from the leading European Cancer Research Center in Lyon and the Centre Léon Bérard, Tollys is located in Lyon, France. The company has raised a total of €6M ($7.1M) from private investors and received a grant of €1.5M ($1.8M) from Bpifrance.
TOLREMO is a privately held, Basel-based Swiss biotechnology company established in 2017 as a spin-off of ETH Zurich, one of the leading science and technology universities in the world. TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of precision therapies to patients with cancer. Our drug development programs are supported by novel transcriptome-based bioinformatics strategies to guide preclinical translation and clinical development. Our drug platform is enabled by deep knowledge of assay development for non-mutational drug resistance, phenotypic and biochemical high-throughput screening, complex image analysis algorithms, medicinal chemistry, structure-based drug design, bioinformatics, and unique preclinical models of drug resistance. These capabilities fuel our drug discovery engine and build a strong platform to identify novel drug resistance and transcriptional regulators and develop small molecule therapies against these promising drug targets.
TOLREMO's lead asset TT125 is a preclinical stage, novel transcriptional modulator that is intended to be used as single agent to treat transcriptome-defined subpopulations of patients with blood cancer. It can also be combined with other targeted cancer drugs to prevent the development of drug resistance in other cancer indications such as lung cancer.
Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. The team at our Flagship European office in Munich has extensive experience supporting clients in strategic and tactical decision-making across the investment cycle.
Invasight is a Swiss-based early-clinical stage biotech start-up that develops first-in-class, protein-protein interaction inhibitors against invasive cancers. Our breakthrough technology, ACINDA accelerates drug discovery and enables precise design of small molecule inhibitors against specific proteins, which cause cancer cell invasion. The most advanced of these first-in-class, protein-protein interaction inhibitors is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.
ACM Biosciences, headquartered in Basel, Switzerland, is a pioneer in polymersome-based development for vaccines and therapeutics. Our lead programs, intramuscular ACM-001 and intranasal ACM-002 (SARS-CoV-2 beta variant protein), completed preclinical development, are in GMP manufacturing and will enter Phase 1 in Q4 2021. The proprietary ACM polymersomes offer a stable, scalable, and plug-and-play platform for encapsulation of mRNA, protein, and peptides.
Asterivir's team has been working for ten years at EPFL on the development of broad-spectrum antiviral drugs capable of being effective not only against existing viruses but also against emerging viruses. The technology has proven to be effective in vitro across a wide range of viruses and has also proven to be effective in vivo against
Influenza, RSV, and HSV2. More recently, they found that their molecules developed against influenza have a good SARS-CoV-2 inhibitory response.
Healiva is a Swiss startup venture located in Lugano developing products for acute to chronic wounds.
We are a patient centric Biotech company, delivering precision medicine by offering a range of products in various application formats for treating acute to chronic wounds. It uses a multi-pronged approach to address patient needs by combining, enzyme technology, medical devices and cell therapy to deliver personalized solutions from bench-to-bedside. To provide patients and healthcare professionals with advanced products and therapies for the wound management by leveraging on best in class innovations.
Limula SA provides a unique platform technology enabling scale out of cell therapy production. Our patented solution is composed of an automation unit and single use kits, allowing to safely manufacture CGT in a decentralised manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments.
MOYA Bio is a startup biotech company developing novel E1 inhibitors for solid and hematological malignancies. Scientific Approach - The clinical success of proteasome inhibitors (e.g., bortezomib or carfilzomib) has piqued interest in targeting other components of the Ubiquitin-Proteasome System as well as closely related Ubiquitin-Like (UBL) pathways. Among these, antagonism of E1 enzymes, which instigate the different UBL cascades, has been highlighted as a promising therapeutic approach in cancer. MOYA Bio has developed a series of novel proprietary E1 antagonists that target specific UBL pathways and posses significant anti-cancer activity, which are currently under preclinical development.
NextImmune, is a spin-off from the Biozentrum, University of Basel, and is focused on the research and development of a novel class of immunosuppressive therapies for autoimmune-inflammatory diseases and organ transplantation.
Onena Medicines was founded by Drs. Neethan Lobo and Maider Zabala Ugalde, who are passionate cancer biology scientists with deep experience in validating novel therapeutic strategies and uncovering drug-resistance mechanisms. Dr. Lobo has over 9 years of professional drug discovery experience in oncology, discovery services and project management, while Dr. Zabala is an expert in cancer target identification and mechanistic validation. During their shared time together at Stanford University, Drs. Zabala and Lobo discovered that a small group of extremely powerful secreted proteins, which they named Dual SMAD Inhibiting Proteins (DSIPs), enable and enhance the body’s organ-specific stem cell populations to rejuvenate themselves through a biological mechanism that had never been described before. They went on to discover that these secreted “immortality” proteins also specifically drive the growth of highly drug-resistant breast cancer cells. This seminal finding led to the creation of Onena Medicines, which is the first company in the world that is building medicines tailored to preventing drug-resistant cancer cells from responding to these special DSIP “immortality” signals.
We are proud to be part of the Basque community. Our Basque origins are reflected in our name: onena means “the best” in the Basque language Euskera. We try to be the best at our work while always remembering the urgency of our patients needs. We strive to help our patients live their best life, their bizitza onena.
Stromal Therapeutics AG is a Swiss biotech company focused on developing new generation immunotherapies against tissue cytokines and their inhibitors, produced by stromal cells. Tissue cytokines are regulated at sites of inflammation, identifying this family of molecules as locally acting, drugable targets in chronic diseases. Stromal Therapeutics’ lead compound demonstrates efficacy in preclinical models of inflammatory heart disease, an indication that has no specific therapy in patients. Stromal Therapeutics’ founders have extensive experience in cardiac inflammation and tissue cytokines and bridge their academic research with the clinics through heading the Translational Cardiology Unit at the University Hospital in Zurich. The company has received bridge funding from BaseLaunch to advance development of their lead compound for the clinical setting. Myocarditis is an inflammatory heart disease and is one of the leading causes of myocardial damage in patients with suspected myocardial infarction with non-obstructive coronary arteries. Patients suffering from acute myocarditis may present to the clinic with acute heart failure, infarct-like symptoms and/or arrhythmic events. Acute cardiac inflammation develops into chronic and potentially lethal inflammatory cardiomyopathy in 20 - 30% of the patients. However, there is no specific treatment available for myocarditis or inflammatory cardiomyopathy. Professor Burkhard Ludewig, one of the academic founders and current president of the board, has received a number of prestigious research grants including the European Research Council Advanced Grant 2020, to study the molecular and cellular basis of inflammatory myocardial disease. The world-leading academic expertise of the founders positions Stromal Therapeutics at the forefront of drug development in the field of cardiac inflammatory diseases. Clinical translation of Stromal Therapeutics' lead compound will be steered by the Translational Cardiology Unit at the University Heart Center, University Hospital Zurich, headed by Professor Ludewig.